Skip to content

Effect of curcumin-piperine in patients with coronavirus (COVID-19)

Effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20121216011763N46
Enrollment
100
Registered
2020-05-04
Start date
2020-05-04
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus (covid-19) disease. COVID-19 Disease

Interventions

Intervention 1: Intervention group: Two curcumin-piperine capsules (500 mg of curcumin + 5 mg of piperine) will be given daily for 2 weeks after lunch and dinner. Intervention 2: Control group: 2 plac

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Tendency to participate in the study People aged 18-65 years Diagnosis of Covid-19 based on the PCR test

Exclusion criteria

Exclusion criteria: Age less than 20 and more than 75 years Taking warfarin Sensitivity to herbal products such as turmeric and pepper

Design outcomes

Primary

MeasureTime frame
CT of the chest. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Find out - Photos - CT.;Body temperature. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: By using clinical thermometer.;Duration of hospitalization. Timepoint: At the time of discharge from the hospital. Method of measurement: By Using the patient's medical record.;Hs-CRP. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic method.;ESR. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic method.;ALT. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;AST. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;LDH. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;BUN. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: urine sample.;Creatinine. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: by laboratory kit.;CBC. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: blood sample.;Blood oxidative stress indices ( SOD, MDA, TAC). Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: By using available commercial kits.;Albumin. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: blood sample.;Severity of the disease. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: By using clinical and laboratory evaluations.;Severity and number of coughs. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Visual analogue scales (VAS) for cough.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Askari

Esfahan University of Medical Sciences

askari@mui.ac.ir+98 31 3668 1378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026